Open forum infectious diseases
Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study
By Córdova E, Rolle CP, Hove K and 22 others.
Abstract
Background
Long-acting cabotegravir plus rilpivirine (CAB+RPV LA) and dolutegravir plus lamivudine (DTG/3TC) are HIV-1 antiretroviral therapy regimens with different administration routes and dosing frequencies, allowing for greater choice.plus.
